Advertisement SELECT was designed to determine whether semaglutide can exert protective cardiovascular effects in patients with overweight or obesity in the absence of diabetes
see the NHS orlistat page for eligibility and guidance), or GLP-1-based therapies such as semaglutide 2.4 mg (Wegovy), which has received MHRA approval and a NICE Technology Appraisal recommendation (NICE TA875) for use in adults with a BMI of 35 kg/m or above (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service Enquire about clinical trial eligibility , if you are interested in accessing investigational medicines through a regulated research pathway your GP or specialist can advise, and you can search for trials via the NIHR 'Be Part of Research' website or ClinicalTrials.gov Discuss realistic expectations , as even the most effective weight loss medicines work best alongside dietary changes, increased physical activity, and behavioural support Your GP can refer you to a specialist weight management service if appropriate
Follow standard or accelerated escalation based on individual response
Two separate 20mg pens, even from the same supplier, carry the risk of minor lot-to-lot variation
Digestive changes
If you understand that Activate is a modest metabolic support supplement and not a pharmaceutical-grade weight loss intervention, you can evaluate it on its actual merits rather than on inflated marketing claims
